All In Biotech

NDA 016831 · Extrovis

Efudex

Fluorouracil · Topical · Nucleoside Metabolic Inhibitor

Last checked: Nov 20, 2026Latest source record: Oct 14, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1970

Jul 29, 1970

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4,755

1,167 Phase 3, 630 recruiting

FAERS reports

78,543

74,311 serious, 11,050 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 23, 2025.

No structured label for this application in openFDA. Older and discontinued products often have none.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 29, 1970 Original approval · Type 3 - New Dosage Form
3 products under this application
  • EFUDEX · FLUOROURACIL 5% · CREAM, TOPICAL · Prescription · TE AB
  • EFUDEX · FLUOROURACIL 2% · SOLUTION, TOPICAL · Prescription · TE AT
  • EFUDEX · FLUOROURACIL 5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, TOPICAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluorouracil" as an intervention, any sponsor and status, largest first.

All 4,755 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea7,137
  • neutropenia5,297
  • nausea5,119
  • vomiting4,068
  • off label use3,678
  • neuropathy peripheral3,555
  • fatigue3,389
  • disease progression3,309
  • pyrexia3,112
  • thrombocytopenia3,047
  • febrile neutropenia2,927
  • anaemia2,621

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,703
20051,704
20061,406
20071,604
20081,857
20091,828
20101,703
20112,392
20122,883
20132,259
20141,910
20152,410
20162,814
20173,247
20184,962
20195,194
20204,341
20214,338
20225,780
20236,345
20246,025
20256,733
20265,105

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Efudex (Fluorouracil)

2024 spending

$47K

Beneficiaries

753

789 claims

Per beneficiary

$62

$1.45 per unit

View as table
YearSpending
2020$30,805
2021$28,797
2022$22,968
2023$20,820
2024$46,636

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8,452 on PubMed

Sponsor: Extrovis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.